Monitoring of acromegaly: What should be performed when GH and IGF-1 levels are discrepant?

Clinical Endocrinology

Volumn 71, Issue 2, 2009, Pages 166-170

  Freda, Pamela U ^a  

^a New York Presbyterian Columbia University Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; SOMATOMEDIN C;

ACROMEGALY; CHEMICAL ANALYSIS; HORMONE RELEASE; HUMAN; MALNUTRITION; ORAL GLUCOSE TOLERANCE TEST; PATIENT MONITORING; PRIORITY JOURNAL; REVIEW; THYROID DISEASE;

ACROMEGALY; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MONITORING, PHYSIOLOGIC;

EID: 67650311783     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2009.03556.x     Document Type: Review

References (48)

1. Freda, P.U., Post, K.D., Powell, J.S. et al. (1998) Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly. Journal of Clinical Endocrinology and Metabolism, 83, 3808 3816. (Pubitemid 28513555)
2. Dimaraki, E.V., Jaffe, C.A., DeMott-Friberg, R. et al. (2002) Acromegaly with apparently normal GH secretion: implications for diagnosis and follow-up. Journal of Clinical Endocrinology and Metabolism, 87, 3537 3542. (Pubitemid 34879493)
3. Freda, P.U. (2003) Current concepts in the biochemical assessment of the patient with acromegaly. Growth Hormone and IGF Research, 13, 171 184. (Pubitemid 36980706)
4. Costa, A.C., Rossi, A., Martinelli Jr., C.E. et al. (2002) Assessment of disease activity in treated acromegalic patients using a sensitive GH assay: should we achieve strict normal GH levels for a biochemical cure? Journal of Clinical Endocrinology and Metabolism, 87, 3142 3147. (Pubitemid 34816356)
5. Chapman, I.M., Hartman, M.L., Straume, M. et al. (1994) Enhanced sensitivity growth hormone (GH) chemiluminescence assay reveals lower postglucose nadir GH concentrations in men than women. Journal of Clinical Endocrinology and Metabolism, 78, 1312 1319. (Pubitemid 24180997)
6. Serri, O., Beauregard, C. Hardy, J. (2004) Long-term biochemical status and disease-related morbidity in 53 postoperative patients with acromegaly. Journal of Clinical Endocrinology and Metabolism, 89, 658 661. (Pubitemid 38269873)
7. Arafat, A.M., Mohlig, M., Weickert, M.O. et al. (2008) Growth hormone response during oral glucose tolerance test: the impact of assay method on the estimation of reference values in patients with acromegaly and in healthy controls, and the role of gender, age, and body mass index. Journal of Clinical Endocrinology and Metabolism, 93, 1254 1262.
8. Freda, P.U., Landman, R.E., Sundeen, R.E. et al. (2001) Gender and age in the biochemical assessment of cure of acromegaly. Pituitary, 4, 163 171. (Pubitemid 34679332)
9. Giustina, A., Barkan, A., Casanueva, F.F. et al. (2000) Criteria for cure of acromegaly: a consensus statement. Journal of Clinical Endocrinology and Metabolism, 85, 526 529. (Pubitemid 32273628)
10. De Marinis, L., Mancini, A., Bianchi, A. et al. (2002) Preoperative growth hormone response to thyrotropin-releasing hormone and oral glucose tolerance test in acromegaly: a retrospective evaluation of 50 patients. Metabolism, 51, 616 621. (Pubitemid 34516517)
11. Mercado, M., Espinosa de los Monteros, A.L., Sosa, E. et al. (2004) Clinical-biochemical correlations in acromegaly at diagnosis and the real prevalence of biochemically discordant disease. Hormone Research, 62, 293 299. (Pubitemid 40069628)
12. Feelders, R.A., Bidlingmaier, M., Strasburger, C.J. et al. (2005) Postoperative evaluation of patients with acromegaly: clinical significance and timing of oral glucose tolerance testing and measurement of (free) insulin-like growth factor I, acid-labile subunit, and growth hormone-binding protein levels. Journal of Clinical Endocrinology and Metabolism, 90, 6480 6489. (Pubitemid 41759303)
13. Pokrajac, A., Wark, G., Ellis, A.R. et al. (2007) Variation in GH and IGF-I assays limits the applicability of international consensus criteria to local practice. Clinical Endocrinology, 67, 65 70. (Pubitemid 46955441)
14. Alexopoulou, O., Bex, M., Abs, R. et al. (2008) Divergence between growth hormone and insulin-like growth factor-I concentrations in the follow-up of acromegaly. Journal of Clinical Endocrinology and Metabolism, 93, 1324 1330.
15. Ho, P.J., Jaffe, C.A., Friberg, R.D. et al. (1994) Persistence of rapid growth hormone (GH) pulsatility after successful removal of GH-producing pituitary tumors. Journal of Clinical Endocrinology and Metabolism, 78, 1403 1410. (Pubitemid 24181012)
16. Ho, K.Y. Weissberger, A.J. (1994) Characterization of 24-hour growth hormone secretion in acromegaly: implications for diagnosis and therapy. Clinical Endocrinology, 41, 75 83. (Pubitemid 24232531)
17. Vierhapper, H., Heinze, G., Gessl, A. et al. (2003) Use of the oral glucose tolerance test to define remission in acromegaly. Metabolism, 52, 181 185. (Pubitemid 36388840)
18. Colao, A., Pivonello, R., Cavallo, L.M. et al. (2006) Age changes the diagnostic accuracy of mean profile and nadir growth hormone levels after oral glucose in postoperative patients with acromegaly. Clinical Endocrinology, 65, 250 256. (Pubitemid 44079691)
19. Rosario, P.W. Furtado, M.S. (2008) Growth hormone after oral glucose overload: revision of reference values in normal subjects. Arquivos Brasileiros de Endocrinologia e Metabologia, 52, 1139 1144.
20. Markkanen, H., Pekkarinen, T., Valimaki, M.J. et al. (2006) Effect of sex and assay method on serum concentrations of growth hormone in patients with acromegaly and in healthy controls. Clinical Chemistry, 52, 468 473. (Pubitemid 43306471)
21. Ronchi, C.L., Varca, V., Giavoli, C. et al. (2005) Long-term evaluation of postoperative acromegalic patients in remission with previous and newly proposed criteria. Journal of Clinical Endocrinology and Metabolism, 90, 1377 1382. (Pubitemid 40463992)
22. Gama, R., Labib, M., Teale, J.D. et al. (1989) Acromegaly with a misleading normal plasma insulin-like growth factor 1. Annals of Clinical Biochemistry, 26, 102 103. (Pubitemid 19044168)
23. Weissberger, A.J., Ho, K.K. Lazarus, L. (1991) Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone (GH) secretion, insulin-like growth factor I, and GH-binding protein in postmenopausal women. Journal of Clinical Endocrinology and Metabolism, 72, 374 381. (Pubitemid 21921702)
24. Clemmons, D.R. (2007) IGF-I assays: current assay methodologies and their limitations. Pituitary, 10, 121 128. (Pubitemid 46863726)
25. Brabant, G. Wallaschofski, H. (2007) Normal levels of serum IGF-I: determinants and validity of current reference ranges. Pituitary, 10, 129 133. (Pubitemid 46863727)
26. Duncan, E. Wass, J.A. (1999) Investigation protocol: acromegaly and its investigation. Clinical Endocrinology, 50, 285 293. (Pubitemid 29166706)
27. Peacey, S.R., Toogood, A.A., Veldhuis, J.D. et al. (2001) The relationship between 24-hour growth hormone secretion and insulin-like growth factor I in patients with successfully treated acromegaly: impact of surgery or radiotherapy. Journal of Clinical Endocrinology and Metabolism, 86, 259 266. (Pubitemid 32109805)
28. Bates, A.S., Evans, A.J., Jones, P. et al. (1995) Assessment of GH status in acromegaly using serum growth hormone, serum insulin-like growth factor-1 and urinary growth hormone excretion. Clinical Endocrinology, 42, 417 423.
29. Kaltsas, G.A., Isidori, A.M., Florakis, D. et al. (2001) Predictors of the outcome of surgical treatment in acromegaly and the value of the mean growth hormone day curve in assessing postoperative disease activity. Journal of Clinical Endocrinology and Metabolism, 86, 1645 1652. (Pubitemid 32374917)
30. Bajuk-Studen, K. Barkan, A. (2008) Assessment of the magnitude of growth hormone hypersecretion in active acromegaly: reliability of different sampling models. Journal of Clinical Endocrinology and Metabolism, 93, 491 496. (Pubitemid 351240821)
31. Hartman, M.L., Veldhuis, J.D., Vance, M.L. et al. (1990) Somatotropin pulse frequency and basal concentrations are increased in acromegaly and are reduced by successful therapy. Journal of Clinical Endocrinology and Metabolism, 70, 1375 1384.
32. Bates, A.S., Vanthoff, W., Jones, J.M. et al. (1995) Does treatment of acromegaly affect life expectancy. Metabolism: Clinical and Experimental, 44, 1 5.
33. Rajasoorya, C., Holdaway, I.M., Wrightson, P. et al. (1994) Determinants of clinical outcome and survival in acromegaly. Clinical Endocrinology, 41, 95 102. (Pubitemid 24232533)
34. Freda, P.U., Nuruzzaman, A.T., Reyes, C.M. et al. (2004) Significance of "abnormal" nadir growth hormone levels after oral glucose in postoperative patients with acromegaly in remission with normal insulin-like growth factor-I levels. Journal of Clinical Endocrinology and Metabolism, 89, 495 500. (Pubitemid 38269847)
35. Minniti, G., Jaffrain-Rea, M.L., Esposito, V. et al. (2003) Evolving criteria for post-operative biochemical remission of acromegaly: can we achieve a definitive cure? An audit of surgical results on a large series and a review of the literature. Endocrine Related Cancer, 10, 611 619. (Pubitemid 38094895)
36. Machado, E.O., Taboada, G.F., Neto, L.V. et al. (2008) Prevalence of discordant GH and IGF-I levels in acromegalics at diagnosis, after surgical treatment and during treatment with octreotide LAR. Growth Hormone and IGF Research, 18, 389 393. (Pubitemid 351958110)
37. Espinosa-de-los-Monteros, A.L., Mercado, M., Sosa, E. et al. (2002) Changing patterns of insulin-like growth factor-I and glucose-suppressed growth hormone levels after pituitary surgery in patients with acromegaly. Journal of Neurosurgery, 97, 287 292. (Pubitemid 34827327)
38. Wass, J.A. (1997) Growth hormone, insulin-like growth factor-I and its binding proteins in the follow-up of acromegaly. Journal of Endocrinology, 155 (Suppl 1 S17 S19 (Discussion S21).
39. Puder, J.J., Nilavar, S., Post, K.D. et al. (2005) Relationship between disease-related morbidity and biochemical markers of activity in patients with acromegaly. Journal of Clinical Endocrinology and Metabolism, 90, 1972 1978. (Pubitemid 40590060)
40. Ayuk, J., Clayton, R.N., Holder, G. et al. (2004) Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. Journal of Clinical Endocrinology and Metabolism, 89, 1613 1617. (Pubitemid 38507910)
41. Swearingen, B., Barker, F.G. II., Katznelson, L. et al. (1998) Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly (see Comments). Journal of Clinical Endocrinology and Metabolism, 83, 3419 3426. (Pubitemid 28500866)
42. Mestron, A., Webb, S.M., Astorga, R. et al. (2004) Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA). European Journal of Endocrinology, 151, 439 446. (Pubitemid 39430260)
43. Beauregard, C., Truong, U., Hardy, J. et al. (2003) Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly. Clinical Endocrinology, 58, 86 91. (Pubitemid 36098853)
44. Holdaway, I.M., Rajasoorya, R.C. Gamble, G.D. (2004) Factors influencing mortality in acromegaly. Journal of Clinical Endocrinology and Metabolism, 89, 667 674. (Pubitemid 38269875)
45. Mukherjee, A., Monson, J.P., Jonsson, P.J. et al. (2003) Seeking the optimal target range for insulin-like growth factor I during the treatment of adult growth hormone disorders. Journal of Clinical Endocrinology and Metabolism, 88, 5865 5870. (Pubitemid 38033064)
46. Damjanovic, S.S., Neskovic, A.N., Petakov, M.S. et al. (2005) Clinical indicators of biochemical remission in acromegaly: does incomplete disease control always mean therapeutic failure? Clinical Endocrinology, 62, 410 417.
47. Carmichael, J.D., Bonert, V.S., Mirocha, J.M. et al. (2008) The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly. Journal of Clinical Endocrinology and Metabolism, 94, 523 527.
48. Grinspoon, S., Clemmons, D., Swearingen, B. et al. (1995) Serum insulin-like growth factor-binding protein-3 levels in the diagnosis of acromegaly. Journal of Clinical Endocrinology and Metabolism, 80, 927 932.